Results 31 to 40 of about 18,434 (234)

GnRH agonist as a luteal support in IVF cycle: mini-review—is there a role?

Middle East Fertility Society Journal, 2022
Background It has been established that assisted reproductive technology (ART) cycles are usually accompanied by a defective luteal phase, and that luteal phase support (LPS) is mandatory to improve reproductive outcomes.
Hasan Maghraby, Amr S. Abdelbadie, Ashraf Aboali, Aboubakr Elnashar   +3 more
doaj   +1 more source

Choosing trigger of ovulation for optimization of in vitro fertilization programs (literature review) [PDF]

Гинекология, 2016
This review presents recent data on the impact of different triggers on the clinical and embryological indicators of the effectiveness of assisted reproductive technology in patients with normal and excessive ovarian response to superovulation ...
S M Eapen, N G Mishiyeva, B A Martazanova, T V Dontsova, S V Pavlovich   +4 more
doaj  

Effect of luteal phase support gonadotropin-releasing hormone agonist on the endometrial receptivity and outcomes of in vitro fertilization programs [PDF]

Гинекология, 2016
Patients with tubal infertility in implantation window period show impaired endometrial receptivity with low implantation potention that is characterized by decrease in mature pinopodes level on endometrium, decreased expression of leukemia inhibitory ...
E M Savelyeva, S G Perminova, T A Demura, D A Strelchenko   +3 more
doaj  

Final oocyte maturation with a dual trigger compared to human chorionic gonadotropin trigger in antagonist co-treated cycles: A randomized clinical trial

Middle East Fertility Society Journal, 2018
Objective: This clinical trial compared the effect of a dual trigger treatment (combination of gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (hCG) and hCG alone on oocyte quality and metaphase II oocytes’ number. Methods:
Ashraf Alleyassin, Marzieh Ghasemi, Marzieh Aghahosseini, Leila Safdarian, Fatemeh Sarvi, Amir Almasi-Hashiani, Sedigheh Hosseinimousa, Aida Najafian, Arezoo Esmailzadeh   +8 more
doaj   +1 more source

Comparison between the modified long gonadotropin-releasing hormone agonist protocol and the non-downregulation protocol in POSEIDON groups: a propensity score matching retrospective cohort study

Frontiers in Endocrinology, 2023
BackgroundIn vitro fertilization (IVF) is the main technique to address the infertility issue in the patient-oriented strategy encompassing individualized oocyte number (POSEIDON) population.
Chunyan Chen, Xinliu Zeng, Hanke Zhang, Qiongqiong Wei, Ying Gao, Lin Liu   +5 more
doaj   +1 more source

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention

Upsala Journal of Medical Sciences, 2020
In this review the advantages of the gonadotropin-releasing hormone agonist (GnRHa) trigger are discussed beyond those immediately associated with ovarian hyperstimulation syndrome (OHSS) prevention.
Juan Carlos Castillo, Thor Haahr, María Martínez-Moya, Peter Humaidan   +3 more
doaj   +1 more source

Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer

Therapeutic Advances in Urology, 2015
Objectives: Gonadotropin-releasing hormone agonists are widely used as androgen deprivation therapy in many men with locally advanced or metastatic prostate cancer. Gonadotropin-releasing hormone agonists are delivered by intramuscular injection every 1,
Thiery Lebret, Mathieu Rouanne, Oleg Hublarov, Viorel Jinga, Lidiya Petkova, Rumen Kotsev, Ioanel Sinescu, Pascale Dutailly   +7 more
doaj   +1 more source

GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines [PDF]

, 2011
Breakthrough Breast CancerBackground: Gonadotrophin releasing hormone (GnRH) analogs lower estrogen levels in pre-menopausal breast cancer patients. GnRH receptor (GnRH-R) activation also directly inhibits the growth of certain cells.
Sims Andrew H, Faratian Dana, Miller, Nicola, Sims, Andrew H., Morgan, Kevin, Miller Nicola, Millar, Robert P., Langdon, Simon P., Ilgin Cagnan, Sims, Andrew, Dana Faratian, Robert P Millar, Meyer, Colette, Simon P Langdon, Colette Meyer, Harrison David J, Cagnan, Ilgin, Nicola Miller, Morgan Kevin, Millar Robert P, David J Harrison, Faratian, Dana, Langdon Simon P, Kevin Morgan, Meyer Colette, Cagnan Ilgin, Andrew H Sims, Harrison, David J.   +27 more
core   +1 more source

Association between duration of gonadotrophin-releasing hormone agonist use and cardiovascular risks: A population-based competing-risk analysis [PDF]

, 2022
Background Although androgen deprivation therapy has known cardiovascular risks, it is unclear if its duration is related to cardiovascular risks.
Kenrick, Kang Liu, Chi Fai Ng, Yan H. A. Lee, Gary Tse, Pias Tang, Jeremy M. Ho Hui, Jeffrey S. K. Chan, Edward C. Dee   +8 more
core   +1 more source

Direct evidence on the efficacy of GnRH agonist in recurrent steroid cell tumor-not otherwise specified

Gynecologic Oncology Reports, 2019
Background: Steroid cell tumor (SCT) not otherwise specified (NOS) is rare and recurrence and metastasis rarely occurs; therefore, reports regarding its treatment are limited.
Tadaharu Nakasone, Tomoko Nakamoto, Akiko Matsuzaki, Hiroshige Nakagami, Yoichi Aoki   +4 more
doaj   +1 more source